Trial Information

Summary: A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover, Adaptive Dose Design, Clinical Trial to Evaluate the Safety and Efficacy of MK-0249 in Treating Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome Appropriately Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy

Male and Female adults that have been diagnosed with Obstructive Sleep Apnea are wanted for a clinical research study of an investigational medication. Qualifying participants must have been using CPAP treatment for at least 2 months. This study involves 6 daytime office visits and 1 overnight visit over a period of approximately 2-3 months. Financial compensation and study related medical exams will be provided for qualified participants. Health insurance is not required and there is no cost for participation.

Eligible candidates must:

• Be between 18 and 64 years of age
• Have Obstructive Sleep Apnea
• Be using CPAP treatment for at least 2 months
• Have a customary bedtime between the hours of 9pm-12am
• Be in good health

If you would like to learn more about participating in this study, please send an e-mail message using the form below.